Biodesix

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biodesix reports robust Q4 revenue growth and expands reimbursement coverage

Biodesix's strong revenue growth and progress in reimbursement coverage underscore its position in the lung diagnostic testing market.
Continued success with newer tests like Nodify XL2 and Nodify CDT presents opportunities for further expansion and increased payer acceptance.

Biodesix reports robust Q1 revenue growth amidst operational challenges

Biodesix's Q1 2023 performance reflects strong revenue growth driven by core lung diagnostics and test volume expansion.
While facing challenges such as increased operating expenses and delayed clinical trials, the company maintains a focus on growth.
Opportunities lie in leveraging their precision tests portfolio, revenue diversification, and strategic investments for future growth.

Biodesix reports robust Q2 earnings, eyes sustained growth trajectory

Biodesix's Q2 2023 performance reflects strong revenue growth and improved margins, driven by core lung diagnostic tests.
While facing challenges in revenue diversification and cost management, the company's focus on clinical utility and growth opportunities remains promising.
With upcoming conference presentations and investor support, Biodesix is poised to sustain growth and advance towards profitability.

Biodesix reports robust Q3 earnings and strategic growth initiatives

Biodesix delivered a strong Q3 performance with revenue growth, improved margins, and cost management.
The company faces challenges in study timelines and commercialization but has opportunities in market expansion and product development.
By focusing on sales force expansion, quality culture, and cost control, Biodesix is positioning itself for future success.
Investors should note the company's resilience, growth potential, and strategic focus on profitability and market expansion.

Biodesix reports robust 2023 performance, eyes sustained growth in 2024

Biodesix's strong 2023 performance in revenue growth and margin improvement sets the stage for sustained growth in 2024.
The company's focus on operational efficiency, market expansion, and test adoption positions it well for future success.
Challenges in sustaining growth momentum and managing costs are balanced by opportunities in market penetration and profitability.
Investments in sales expansion and ongoing clinical studies present avenues for continued growth and innovation in the coming year.

Biodesix reports robust Q1 performance, focuses on growth strategies

Biodesix's Q1 2024 performance reflects strong revenue growth and operational achievements, despite a net loss.
Strategic partnerships and financial initiatives position the company well for future growth and innovation.
Addressing profitability challenges and operational efficiency will be key for Biodesix's sustained success in the competitive healthcare market.

Biodesix reports robust Q2 growth, raises revenue guidance for 2024

Biodesix's Q2 2024 performance reflects strong revenue growth and operational improvements, despite some profitability challenges.
The company's focus on innovation in lung cancer care and positive workplace culture position it well for future success.
With increased revenue guidance, expanding market opportunities, and a commitment to impact healthcare, Biodesix shows promise for continued growth.

Biodesix reports robust Q3 performance amidst revenue growth challenges

Biodesix demonstrated strong financial performance in Q3 2024 with revenue growth, improved margins, and a focus on innovation.
While facing challenges in biopharma services revenue and operational disruptions, the company remains resilient and proactive.
Opportunities lie in revenue growth through lung volume increase, addressing payment issues, and expanding sales team effectiveness.
Overall, Biodesix's strategic focus on growth and efficiency positions it well for future success in the diagnostics market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the Healthcare Technology Report's Top 100 Healthcare Technology Companies of 2022. The company develops and commercializes blood-based diagnostic tests designed to address important unmet needs in healthcare, by combining multi-omics through the power of artificial intelligence. Biodesix offers five non-invasi

Biodesix Named a Top 100 Healthcare Technology Company of 2022

Biodesix, Inc. (NASDAQ:BDSX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Max Masucci - Cowen Kyle Mikson - Canaccord Operator Good morning. My name is Joanne and I will be your conference operator today.

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2022 Results - Earnings Call Transcript

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update. “We are thrilled to announce strong growth from our core lung diagnostic testing, with an increase in revenue of 52% over the second quarter of 2021 and 56% over the first quarter of 2022,” said Scott Hutton, CEO of Biodesix. “Wit

Biodesix Announces Second Quarter 2022 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022. Canaccord Genuity 42nd Annual Growth Conference Date: Wednesday, August 10, 2022 Time: 3:00 PM ET Location: InterContinental Boston The presentation will be webcast live and available for r

Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and Oncology) Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC2022) on Aug

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day. Dial-in and call details are a

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix's De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test. The Nodify CDT test is a part of the Biodesix's blood-based Nodify Lung® Nodule Risk Assessment testing strategy consisting of two tests to a

Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment o

Biodesix Announces Research Agreement with Top US Cancer Center

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL. 42nd Annual William Blair Growth Stock Conference Date: Wednesday, June 8, 2022 Time: 9:20 a.m. CT In addition to the presentation, the management t

Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference

Biodesix has been a terrible business and stock since its offering. Even a short-lived pandemic-related momentum run could not inspire confidence or profits.

Biodesix: Bad Diagnosis

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022. H.C. Wainwright Global Investment Conference Date: Tuesday, May 24, 2022 Pre-recorded on-demand presentation available beginning at 7:00 AM ET The on-demand presentation will be availa

Biodesix to Present at the H.C. Wainwright Global Investment Conference

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022, in San Francisco, California. Data from the abstract titled

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference

Biodesix, Inc. (NASDAQ:BDSX ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Chris Brinzey - IR Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Brian Weinstein - William Blair & Company Kyle Mikson - Canaccord Genuity Max Masucci - Cowen and Company Operator Hello. Thank you for standing by, and welcome to Biodesix First Quarter 2022 Earnings Conference Call.

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2022 Results - Earnings Call Transcript

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for first quarter ended March 31, 2022 and provided a corporate update. “We are pleased by the progress we continue to make with our core lung diagnostic sales revenue, which grew 17% over the first quarter 2021 despite significant disruption from the COVID-19 Omicron variant during the first half of

Biodesix Announces First Quarter 2022 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on Wednesday, May 11. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. Eastern Time on the same day. Dial-in and call details are as

Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 6,508,376 common shares on April 7, 2022 in a private placement offering that raised approximately $11.7 million in net proceeds to, among other things, fund the partial repayment of its existing term loan and general corporate purposes, including our strategic growth. In addition, the Company entered into a Third Amendment to its

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.” This peer-reviewed publication further validates the GeneStrat NGS test and t

Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer

Biodesix, Inc. (BDSX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Biodesix, Inc. (BDSX) Looks Ripe for Bottom Fishing

Biodesix, Inc. (BDSX) CEO Scott Hutton on Q4 2021 Results - Earnings Call Transcript

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended December 31, 2021 (fiscal 2021) and provided a corporate update. “Despite the ongoing challenges caused by the global pandemic, the fourth quarter and fiscal 2021 were very productive,” said Scott Hutton, CEO of Biodesix. “Most notably, we successfully executed on

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Under the terms of the purchase agreement, Biodesix will have the right at its sole discretion, but not the obligation, to sell

Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. In this body of work, the PIR test provided two classifications of PIR-Not Resistant and PIR-Resistant predictive of likely response to immune checkpoint inhibitors (ICIs). The data showed that the Biodesix PIR test was

News for Biodesix Stock (BDSX)